The estimated Net Worth of Stephen L Sabba is at least $4.2 million dollars as of 5 March 2024. Stephen Sabba owns over 2,893 units of Ligand Pharmaceuticals stock worth over $3,177,131 and over the last 15 years he sold LGND stock worth over $661,890. In addition, he makes $359,900 as Independent Director at Ligand Pharmaceuticals.
Stephen has made over 9 trades of the Ligand Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 2,893 units of LGND stock worth $298,239 on 5 March 2024.
The largest trade he's ever made was exercising 14,670 units of Ligand Pharmaceuticals stock on 9 February 2021 worth over $166,211. On average, Stephen trades about 1,280 units every 155 days since 2009. As of 5 March 2024 he still owns at least 30,819 units of Ligand Pharmaceuticals stock.
You can see the complete history of Stephen Sabba stock trades at the bottom of the page.
Dr. Stephen L. Sabba M.D. serves as Independent Director of the Company. Dr. Sabba has been a leading Bio/Pharma Analyst and Fund Manager for Knott Partners, L.P., an investment fund company, since November 2006. Previously he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago-based Health Care hedge fund. Prior to that, Dr. Sabba was Director of Research at Sturza’s Medical Research, and previously was a gastroenterologist and internist in private practice at Phelps Hospital in North Tarrytown, New York. He received his M.D. from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a B.S. with honors at Cornell University. Dr. Sabba has served as a member of the board of the directors for Novelion Therapeutics Inc., a leading Canadian biotech company since June 2012. Dr. Sabba’s experience in accounting and capital markets and deep knowledge of the biopharmaceutical industry, including his background as a medical doctor, contributed to our board of directors’ conclusion that he should serve as a director of our company.
As the Independent Director of Ligand Pharmaceuticals, the total compensation of Stephen Sabba at Ligand Pharmaceuticals is $359,900. There are 11 executives at Ligand Pharmaceuticals getting paid more, with John Higgins having the highest compensation of $6,770,380.
Stephen Sabba is 60, he's been the Independent Director of Ligand Pharmaceuticals since 2008. There are 2 older and 14 younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals, Inc. is John Lamattina, 70, who is the Independent Director.
Stephen's mailing address filed with the SEC is 485 UNDERHILL BLVD., , SYOSSETT, NY, 11791.
Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.
ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
Ligand Pharmaceuticals executives and other stock owners filed with the SEC include: